Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis
RI Mincu, AA Mahabadi, L Michel, SM Mrotzek… - JAMA network …, 2019 - jamanetwork.com
Importance Cardiovascular adverse events (CVAEs) after treatment with BRAF and MEK
inhibitors in patients with melanoma remain incompletely characterized. Objective To
determine the association of BRAF and MEK inhibitor treatment with CVAEs in patients with
melanoma compared with BRAF inhibitor monotherapy. Data Sources PubMed, Cochrane,
and Web of Science were systematically searched for keywordsvemurafenib, dabrafenib,
encorafenib, trametinib, binimetinib, andcobinimetinibfrom database inception through …
inhibitors in patients with melanoma remain incompletely characterized. Objective To
determine the association of BRAF and MEK inhibitor treatment with CVAEs in patients with
melanoma compared with BRAF inhibitor monotherapy. Data Sources PubMed, Cochrane,
and Web of Science were systematically searched for keywordsvemurafenib, dabrafenib,
encorafenib, trametinib, binimetinib, andcobinimetinibfrom database inception through …
